Edgewise Therapeutics Quarterly Cash Flow Statement
NASDAQ: EWTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
39.06-0.17 (-0.43%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Edgewise Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Edgewise Therapeutics generated -$42.5 million of operating cash flow and spent $32,000 on capital expenditures. That left free cash flow of -$42.5 million.
Summary generated from market data by MetaCap's automated system. Methodology
Edgewise Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -57.33M | -49.01M | -50.22M | -40.67M | -36.12M | -40.80M | -39.66M | -34.13M | -31.50M | -28.52M | -30.14M | -25.71M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 500.00K | 537.00K | 525.00K | 500.00K | 500.00K | 513.00K | 577.00K | 500.00K | 500.00K | 473.00K | 483.00K | 400.00K |
| Stock-Based Compensation | 9.36M | 8.71M | 9.88M | 8.09M | 7.73M | 9.06M | 7.74M | 6.88M | 5.22M | 4.87M | 5.15M | 4.56M |
| Change in Working Capital | 202.00K | 4.49M | -3.02M | -3.43M | -2.62M | 1.38M | 1.68M | -237.00K | 2.87M | 717.00K | -1.76M | 605.00K |
| Operating Cash Flow | -42.47M | -42.54M | -38.59M | -34.78M | -32.58M | -37.87M | -26.96M | -27.37M | -26.10M | -28.60M | -26.83M | -22.06M |
| Capital Expenditures | -32.00K | -260.00K | -73.00K | -89.00K | -50.00K | -44.00K | -274.00K | -520.00K | -221.00K | -297.00K | -161.00K | -457.00K |
| Investing Cash Flow | 78.49M | 2.43M | 49.76M | 35.72M | -162.17M | 43.90M | 20.92M | 25.36M | 37.37M | -268.31M | 26.98M | 23.42M |
| Financing Cash Flow | 3.09M | 12.17M | 3.98M | 1.66M | 188.23M | 2.22M | 2.90M | 3.33M | 1.95M | 241.07M | 52.99M | -211.00K |
| Net Change in Cash | 39.11M | -27.94M | 15.14M | 2.60M | -6.52M | 8.26M | -3.14M | 1.32M | 13.22M | -55.83M | 53.14M | 1.15M |
| Free Cash Flow | -42.50M | -42.80M | -38.66M | -34.87M | -32.63M | -37.91M | -27.23M | -27.89M | -26.32M | -28.89M | -26.99M | -22.52M |
This table shows 12 quarterly periods of Edgewise Therapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow EWTX's reporting calendar. What is a cash flow statement?